Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

PURPOSE: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michael L., Jurczak, Wojciech, Zinzani, Pier Luigi, Eyre, Toby A., Cheah, Chan Y., Ujjani, Chaitra S., Koh, Youngil, Izutsu, Koji, Gerson, James N., Flinn, Ian, Tessoulin, Benoit, Alencar, Alvaro J., Ma, Shuo, Lewis, David, Lech-Maranda, Ewa, Rhodes, Joanna, Patel, Krish, Maddocks, Kami, Lamanna, Nicole, Wang, Yucai, Tam, Constantine S., Munir, Talha, Nagai, Hirokazu, Hernandez-Ilizaliturri, Francisco, Kumar, Anita, Fenske, Timothy S., Seymour, John F., Zelenetz, Andrew D., Nair, Binoj, Tsai, Donald E., Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao, Zhao, Junjie, Mato, Anthony R., Shah, Nirav N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461952/
https://www.ncbi.nlm.nih.gov/pubmed/37192437
http://dx.doi.org/10.1200/JCO.23.00562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461952/
https://www.ncbi.nlm.nih.gov/pubmed/37192437
http://dx.doi.org/10.1200/JCO.23.00562

Ejemplares similares